Clinical Research Directory

Inclusion Criteria: * Male or female, 25-65 years of age, in general good health. * Seeking a reduction in the appearance of periorbital wrinkles. * Bilateral and approximately symmetrical periorbital wrinkles with a Fitzpatrick Wrinkle Classification Scale (FWCS) score 4-9, as assessed by the treating investigator. * Fitzpatrick skin type I-V. * Able to understand the study requirements and sign an EC/IRB-approved informed consent form prior to any study procedures. * Willing and able to comply with the treatment and follow-up schedule, pre- and post-treatment instructions, and allow standardized photography. * Willing to withhold additional aesthetic therapies to the treatment area (e.g., fillers, resurfacing procedures) for the entire study duration. Exclusion Criteria: * Known bleeding disorder (e.g., thrombocytopenia, thrombasthenia, von Willebrand's disease). * Immunocompromised or immunosuppressed (e.g., AIDS, HIV, or immunosuppressive therapy). * Planned or recent use of anti-platelets, anti-coagulants, thrombolytics, ACE inhibitors, vitamin E, or anti-inflammatory drugs from 1 week prior to 1 month after treatment. * Systemic corticosteroid or anabolic steroid use within 30 days prior to enrollment (standard inhaled/nasal corticosteroids are permitted). * Use of weight loss medications before or during the study. * History of chronic or recurrent infection or inflammation that would preclude participation. * Severe allergies with history of anaphylaxis. * History of malignancy within 5 years prior to enrollment. * Infection, inflammation, or active dermatologic disease in the face. * Pregnant, breastfeeding, or planning pregnancy during the study; women of childbearing potential not using reliable contraception for ≥3 months prior and throughout the study. * Exposure to an investigational drug or device within 3 months prior to enrollment or during the study. * Prior permanent facial injections (e.g., silicone, grafting) or any upper-face surgery. * Neurotoxin treatments in the upper face within 6 months prior to enrollment. * Semi-permanent filler (e.g., collagen, CaHA) or any dermal filler (e.g., hyaluronic acid) in the upper face within 18 months prior to enrollment. * Any active or passive implant in the treatment area (metallic, silicone, electronic, or injected chemical substance). * Initiation of over-the-counter anti-wrinkle products (e.g., alpha-hydroxy acids) or prescription treatments (e.g., Retin-A, micro-dermabrasion, chemical peels) within 4 weeks prior to enrollment or planned use during the study. * Occupations involving continuous or routine sun exposure (e.g., lifeguards, outdoor workers). * History of smoking within the past 5 years. * Planned bariatric surgery or recent drastic weight loss. * Unstable body weight during the study. * Any other medical condition, laboratory abnormality, or investigator judgment that could affect compliance, safety, or data integrity.